Not Yet Recruiting
NA
INTERVENTIONAL
NCT06607926
Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study aims to explore the efficacy and safety of thymosin α-1 (Tα1) plus chemotherapy and PD-1 inhibitors as neoadjuvant therapy for operable non-small cell lung cancer
Interventions
Name:
Thymosin Alpha 1
Type:
DRUG
Description:
4.8 mg subcutaneous injection twice weekly over 12 weeks
Name:
Tislelizumab
Type:
DRUG
Description:
200mg, IV, d1 of each 21-d cycle, four cycles
Name:
Platinum-doublet chemotherapy
Type:
DRUG
Description:
Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.
Primary Outcomes
Measure:
Pathologic complete response rate
TimeFrame:
at the time of surgey
Description:
The rate of no viable tumor cells in the resected specimen including lymph node region evaluated by H\&E staining
Trial Information
NCT ID
NCT06607926
Status
Not Yet Recruiting
Study Type
INTERVENTIONAL
Phases
NA
Sponsor
Xuanwu Hospital, Beijing
Last Updated
December 15, 2025